24.3 C
New York
Wednesday, June 3, 2026

Tag: milestone payments

newssourceFORcompanyinformationcontent1marketreleases

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR

Applied Therapeutics Reports Second Quarter 2025 Financial Results

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

Undervalued Gold Equities Poised for a Breakout

Equity Insider News CommentaryIssued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- Late last week as global equities rose,...

Undervalued Gold Equities Poised for a Breakout

Equity Insider News CommentaryIssued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 12, 2025 /CNW/ -- Late last week as global equities rose,...

Undervalued Gold Equities Poised for a Breakout

Equity Insider News CommentaryIssued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- Late last week as global equities rose,...

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License...

The Next Gold Boom May Not Be in Bullion–It’s in the Miners

Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – On the brink of...

The Next Gold Boom May Not Be in Bullion–It’s in the Miners

Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 8, 2025 /CNW/ -- USA News Group News Commentary – On the brink of...

The Next Gold Boom May Not Be in Bullion–It’s in the Miners

Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, BC, Aug. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – On the brink of...

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – 
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

SEACOR Marine Announces Second Quarter 2025 Results

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- SEACOR Marine Holdings Inc. (NYSE: SMHI) (the “Company” or “SEACOR Marine”), a leading provider of marine and support transportation services to offshore energy facilities worldwide, today announced results for its second quarter ended June 30, 2025.

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMilestone payments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers